应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SWTX SpringWorks Therapeutics, Inc.
盘前交易 02-19 08:55:07 EST
56.30
-1.13
-1.97%
盘前
55.15
-1.15
-2.04%
08:52 EST
最高
57.00
最低
55.01
成交量
378.36万
今开
55.80
昨收
57.43
日振幅
3.47%
总市值
41.87亿
流通市值
38.86亿
总股本
7,437万
成交额
2.12亿
换手率
5.48%
流通股本
6,902万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
HC Wainwright & Co.:重申SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。
金融界 · 02-12
HC Wainwright & Co.:重申SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。
异动解读 | FDA批准SpringWorks遗传疾病新药,公司盘后大涨7.02%
异动解读 · 02-11
异动解读 | FDA批准SpringWorks遗传疾病新药,公司盘后大涨7.02%
异动解读 | 默克有意收购引发SpringWorks股价盘后大跌近6%
异动解读 · 02-11
异动解读 | 默克有意收购引发SpringWorks股价盘后大跌近6%
美国 FDA 批准 SpringWorks 的遗传性疾病药物
路透中文 · 02-11
美国 FDA 批准 SpringWorks 的遗传性疾病药物
美国 FDA 批准 Springworks 公司的遗传性疾病药物
路透中文 · 02-11
美国 FDA 批准 Springworks 公司的遗传性疾病药物
异动解读 | 因医药巨头默克洽购传闻 SpringWorks Therapeutics盘中大跌5%
异动解读 · 02-11
异动解读 | 因医药巨头默克洽购传闻 SpringWorks Therapeutics盘中大跌5%
今日优惠-合并与收购
路透中文 · 02-11
今日优惠-合并与收购
默沙东(MRK)正就收购美国制药商SpringWorks(SWTX)进行深入谈判
金吾财讯 · 02-11
默沙东(MRK)正就收购美国制药商SpringWorks(SWTX)进行深入谈判
默克洽购美国生物制药公司SpringWorks
新浪财经 · 02-11
默克洽购美国生物制药公司SpringWorks
重发-更新版 1-独家-德国默克就收购美国生物技术公司 SpringWorks 进行深入谈判
路透中文 · 02-11
重发-更新版 1-独家-德国默克就收购美国生物技术公司 SpringWorks 进行深入谈判
美股异动 | SpringWorks Therapeutics(SWTX.US)大涨34% 与默克洽谈收购事项
智通财经 · 02-11
美股异动 | SpringWorks Therapeutics(SWTX.US)大涨34% 与默克洽谈收购事项
独家-德国默克公司就收购美国生物技术公司 Springworks 进行深入谈判
路透中文 · 02-10
独家-德国默克公司就收购美国生物技术公司 Springworks 进行深入谈判
独家-消息人士称,德国默克公司正在洽谈收购美国癌症生物技术公司 Springworks
路透中文 · 02-10
独家-消息人士称,德国默克公司正在洽谈收购美国癌症生物技术公司 Springworks
Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.14%
市场透视 · 02-04
Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.14%
【券商聚焦】摩根大通:2025年1月美国分析师关注名单出炉
金吾财讯 · 01-24
【券商聚焦】摩根大通:2025年1月美国分析师关注名单出炉
Springworks Therapeutics, Inc.盘中异动 股价大跌8.95%
市场透视 · 01-13
Springworks Therapeutics, Inc.盘中异动 股价大跌8.95%
Guggenheim:维持SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由80.00美元调整至78.00美元。
金融界 · 01-08
Guggenheim:维持SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由80.00美元调整至78.00美元。
Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.65%
市场透视 · 01-07
Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.65%
Springworks Therapeutics, Inc.盘中异动 股价大涨5.01%
市场透视 · 2024-12-04
Springworks Therapeutics, Inc.盘中异动 股价大涨5.01%
Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.03%报41.37美元
市场透视 · 2024-11-26
Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.03%报41.37美元
加载更多
公司概况
公司名称:
SpringWorks Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
SpringWorks Therapeutics, Inc.于2017年8月在特拉华州成立。该公司是一家临床阶段的生物制药公司,它使用精密医学来为患有严重疾病和癌症的服务不足的患者人群获取,开发和商品化改变生命的药物。
发行价格:
--
{"stockData":{"symbol":"SWTX","market":"US","secType":"STK","nameCN":"SpringWorks Therapeutics, Inc.","latestPrice":56.3,"timestamp":1739912400000,"preClose":57.43,"halted":0,"volume":3783579,"hourTrading":{"tag":"盘前","latestPrice":55.15,"preClose":56.3,"latestTime":"08:52 EST","volume":831,"amount":46638.999957,"timestamp":1739973149138},"delay":0,"floatShares":69020420,"shares":74365180,"eps":-3.828354,"marketStatus":"盘前交易","change":-1.13,"latestTime":"02-19 08:55:07 EST","open":55.8,"high":57,"low":55.01,"amount":211512508.77804,"amplitude":0.034651,"askPrice":56.21,"askSize":300,"bidPrice":55.15,"bidSize":375,"shortable":3,"etf":0,"ttmEps":-3.828354,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1739975400000},"marketStatusCode":1,"adr":0,"listingDate":1568347200000,"exchange":"NASDAQ","adjPreClose":56.3,"preHourTrading":{"tag":"盘前","latestPrice":55.15,"preClose":56.3,"latestTime":"08:52 EST","volume":831,"amount":46638.999957,"timestamp":1739973149138},"postHourTrading":{"tag":"盘后","latestPrice":56.72,"preClose":56.3,"latestTime":"19:59 EST","volume":290997,"amount":16385080.256,"timestamp":1739926796951},"volumeRatio":0.5532055674075851,"impliedVol":1.2158,"impliedVolPercentile":0.936},"requestUrl":"/m/hq/s/SWTX","defaultTab":"news","newsList":[{"id":"2510049376","title":"HC Wainwright & Co.:重申SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510049376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510049376?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:55","pubTimestamp":1739364948,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12205548120951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","SWTX"],"gpt_icon":0},{"id":"1124949677","title":"异动解读 | FDA批准SpringWorks遗传疾病新药,公司盘后大涨7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124949677","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124949677?lang=zh_cn&edition=full","pubTime":"2025-02-12 06:58","pubTimestamp":1739314708,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司在盘后交易中股价大涨7.02%,引起了市场广泛关注。根据新闻报道,导致该公司股价大涨的主要原因是:美国食品药品监督管理局 批准了SpringWorks的新药Gomekli用于治疗一种罕见的遗传性疾病。之前只有阿斯利康公司的Koselugo获批用于治疗NF1儿童患者,而SpringWorks的Gomekli则是首个获批可用于成人和2岁及以上儿童患者的NF1口服药物。此外,据报道默克公司正在就收购SpringWorks进行深入谈判。如果收购成功,将进一步帮助这家生物科技公司推广新获批药物并拓展产品线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"1148552946","title":"异动解读 | 默克有意收购引发SpringWorks股价盘后大跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148552946","media":"异动解读","labels":["merge","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148552946?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:54","pubTimestamp":1739310872,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司今日盘后股价大跌近6%,引发市场关注。\n\n根据相关报道,德国医药巨头默克公司正在就收购SpringWorks进行深入谈判,这是导致该股价暴跌的主要原因。\n\n作为一家专注罕见病和肿瘤药物研发的生物制药公司,SpringWorks去年底刚推出治疗罕见肿瘤的药品Ogsiveo,还有望获批另一潜在重磅新药。这或许吸引了默克公司的兴趣,进而与SpringWorks进行谈判。分析称,若收购成功,将有利于默克加强在生物制药和罕见病领域的布局。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge,movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"2510350976","title":"美国 FDA 批准 SpringWorks 的遗传性疾病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2510350976","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510350976?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:35","pubTimestamp":1739309719,"startTime":"0","endTime":"0","summary":"更新版 2-美国 FDA 批准 SpringWorks 的遗传性疾病药物第4-6段和第12段增加了背景介绍,第7、10段增加了药物详情,第8段增加了公司高管评论。路透2月11日 - 美国食品和药物管理局周二表示,已批准SpringWorks Therapeutics公司的SWTX.O药物用于治疗一种罕见的遗传性疾病,这种疾病会导致肿瘤在覆盖全身神经的组织中生长。SpringWorks 的 Gomekli 属于被称为 MEK 抑制剂的一类药物,旨在抑制 MEK1 和 MEK2 蛋白类型。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4T3P21TU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SWTX","BK4139"],"gpt_icon":0},{"id":"2510071354","title":"美国 FDA 批准 Springworks 公司的遗传性疾病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2510071354","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510071354?lang=zh_cn&edition=full","pubTime":"2025-02-12 04:57","pubTimestamp":1739307424,"startTime":"0","endTime":"0","summary":"美国 FDA 批准 Springworks 公司的遗传性疾病药物路透2月11日 - 美国食品和药物管理局周二批准了 Springworks Therapeutics公司的SWTX.O药物,用于治疗一种罕见的遗传性疾病,这种疾病会导致肿瘤长在全身的神经上。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4S3P21OI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SWTX","BK4139"],"gpt_icon":0},{"id":"1164462951","title":"异动解读 | 因医药巨头默克洽购传闻 SpringWorks Therapeutics盘中大跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164462951","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164462951?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:44","pubTimestamp":1739288665,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司今日盘中大幅下跌5%,引发了市场的广泛关注。据相关报道,导致该股暴跌的主要原因是德国医药公司默克正在就收购该公司进行深入谈判。而SpringWorks是一家专注于开发科创药物的生物制药公司,主要研究内容针对多种罕见疾病和癌症。伴随SpringWorks产品线的不断壮大,或许吸引了以默克为首的业内巨头。因此,市场分析认为,默克此次收购SpringWorks,有望为其未来发展注入新的动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"2510246387","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2510246387","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510246387?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:43","pubTimestamp":1739285027,"startTime":"0","endTime":"0","summary":"今日优惠-合并与收购路透2月11日 - 截至格林尼治标准时间周二 14 时 30 分,已报道的竞购、兼并、收购和处置情况如下:** 瑞士制药巨头诺华< NOVN.S >已同意以不超过 31 亿美元的价格收购黑石集团BX.N 药物开发部门拥有多数股权的生物制药公司 Anthos Therapeutics,以增强其心血管业务。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4S3P216X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZPN","LU0310800379.SGD","LU0708994859.HKD","EMR","SG9999011175.SGD","BK4135","BX","BK4532","LU1064131342.USD","SWTX","GB00BDT5M118.USD","SG9999003800.SGD","IE00BGHQF748.EUR","LU1791807156.HKD","BK4534","BK4588","FOXA","IE00BVYPNV92.GBP","BK4139","BK4581","LU0128525929.USD","IE00B3QW5Z07.USD","BK4585","BK4551","LU1201861249.SGD","IE00BVYPNW00.USD","LU0648001328.SGD","BK4554","LU0011850046.USD","LU0130102774.USD","LU1069347547.HKD","SG9999014039.USD","SCHW","SG9999001077.SGD","BK4507","IE00B42XCP33.USD","SG9999015978.USD","BK4023","LU2360107671.USD","IE00B3PB1722.GBP","IE00BLSP4452.SGD","JKHY","IE00BDGV0183.EUR","BK4127","BK4543","LU1153585028.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0130517989.USD"],"gpt_icon":1},{"id":"2510487281","title":"默沙东(MRK)正就收购美国制药商SpringWorks(SWTX)进行深入谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2510487281","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510487281?lang=zh_cn&edition=full","pubTime":"2025-02-11 16:28","pubTimestamp":1739262495,"startTime":"0","endTime":"0","summary":"金吾财讯 | 默沙东(MRK)周一表示,正就收购美国癌症和罕见疾病制药商SpringWorks Therapeutics(SWTX)进行深入谈判。据媒体当天早些时候援引三位消息人士称,如果谈判成功,可能会在未来几周签署协议。他们没有透露正在讨论的具体条款。总部位于康涅狄格州斯坦福的SpringWorks于2019年在纽约上市,是一家商业阶段的生物技术公司,开发用于治疗各种癌症的药物,包括罕见肿瘤和子宫癌。美国医疗保健行业的交易活动在2024年有所放缓后,目前正显示出回暖的迹象。强生公司上个月同意以约146亿美元收购Intra-Cellular Therapeutics。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285295","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","LU0203345920.USD","LU1057294990.SGD","BK4533","LU1037948541.HKD","BK4559","LU2089984988.USD","LU1917777945.USD","BK4534","LU0265550946.USD","LU0058720904.USD","BK1191","SG9999014567.USD","IE00BN8TJ469.HKD","BK4585","LU1571399168.USD","LU1066051498.USD","SG9999001176.SGD","IE00B2B36J28.USD","LU1974910355.USD","01477","LU2324357040.USD","LU1162221912.USD","LU0965509010.AUD","IE000M9KFDE8.USD","IE0002141913.USD","LU1116320737.USD","SG9999002232.USD","LU0203347892.USD","LU0320765489.SGD","LU0289739699.SGD","MRK","LU0211331839.USD","LU1023059063.AUD","LU1093756325.SGD","LU1291159041.SGD","SG9999014575.USD","LU0122379950.USD","LU0861579265.USD","LU0965508806.USD","LU2361044949.HKD","LU1983299246.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU0985320562.USD","LU1066053197.SGD","LU0070302665.USD","LU1699723380.USD","SG9999013999.USD","SWTX"],"gpt_icon":0},{"id":"1144010287","title":"默克洽购美国生物制药公司SpringWorks","url":"https://stock-news.laohu8.com/highlight/detail?id=1144010287","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144010287?lang=zh_cn&edition=full","pubTime":"2025-02-11 15:59","pubTimestamp":1739260784,"startTime":"0","endTime":"0","summary":"关键条件尚未满足。","market":"us","thumbnail":"https://static.tigerbbs.com/b4dc3092ae6ffcac01edfc3590364a28","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b4dc3092ae6ffcac01edfc3590364a28"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-02-11/doc-inekawwf6692871.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"默克洽购美国生物制药公司SpringWorks","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"XLCJ","symbols":["SWTX"],"gpt_icon":0},{"id":"2510384896","title":"重发-更新版 1-独家-德国默克就收购美国生物技术公司 SpringWorks 进行深入谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2510384896","media":"路透中文","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510384896?lang=zh_cn&edition=full","pubTime":"2025-02-11 08:52","pubTimestamp":1739235129,"startTime":"0","endTime":"0","summary":"重发-更新版 1-独家-德国默克就收购美国生物技术公司 SpringWorks 进行深入谈判将倒数第三段改为 \"LOEs\",而不是 \"LOEs\"。路透纽约/法兰克福2月11日 - 德国医疗保健与科技集团默克公司周一表示,该公司正在就收购美国癌症与罕见病制药商SpringWorks Therapeutics SWTX.O进行深入谈判。SpringWorks 拒绝对此发表评论。SpringWorks 的股价周一收盘上涨 34%,市值约为 40 亿美元。战略赌注 对 SpringWorks 公司的交易将成为默克公司近年来最大的医药交易之一,并将推动其建立癌症治疗产品线的努力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4T3P2023:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU1989772840.SGD","LU1674673428.USD","BK4581","SGXZ57979304.SGD","LU1037948897.HKD","BK4568","LU2112291526.USD","SG9999014575.USD","BK4007","LU1718418525.SGD","LU2430703251.USD","LU2023250504.SGD","LU1244550221.USD","LU0345769631.USD","LU1585245621.USD","SWTX","LU1196500208.SGD","LU1894683348.USD","LU0965509101.SGD","BK4550","LU1934455277.USD","LU0265550946.USD","LU0985320562.USD","LU2023250843.SGD","IE00BDGV0183.EUR","MRK","LU1061106388.HKD","JNJ","LU1035773651.USD","IE00B2B36J28.USD","LU0203347892.USD","LU0234570918.USD","LU1280957306.USD","LU1032466523.USD","LU1674673691.USD","LU0345769128.USD","LU1032955483.USD","LU1267930813.SGD","SG9999014559.SGD","IE00B19Z3581.USD","LU2430703095.HKD","BK4504","LU1037948541.HKD","LU0466842654.USD","LU2133065610.SGD","IE00B4R5TH58.HKD","LU0098860793.USD","LU1914381329.SGD","LU1935042991.SGD"],"gpt_icon":1},{"id":"2510810268","title":"美股异动 | SpringWorks Therapeutics(SWTX.US)大涨34% 与默克洽谈收购事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2510810268","media":"智通财经","labels":["corporation","merge","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510810268?lang=zh_cn&edition=full","pubTime":"2025-02-11 08:21","pubTimestamp":1739233299,"startTime":"0","endTime":"0","summary":"智通财经获悉,默克公司表示,收购美国癌症和罕见疾病制药公司SpringWorks Therapeutics的谈判正在进行中,这使得这家美国癌症和罕见疾病制药公司的股价周一飙升34%,市值超过40亿美元。总部位于德国的默克公司证实了这一报道。SpringWorks的一种药物Ogsiveo在美国被批准用于治疗成人结缔组织肿瘤。彭博分析师Michael Shah在一份报告中表示,收购SpringWorks将补充默克的肿瘤业务,到2030年,每年的销售额可能会增加15亿欧元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1248104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2106854487.HKD","IE00BJJMRZ35.SGD","LU1291159041.SGD","BK4585","LU2461242641.AUD","LU0320765646.SGD","IE00BSNM7G36.USD","LU0106261372.USD","LU1917777945.USD","LU2023250504.SGD","LU1974910355.USD","LU0965508806.USD","LU1585245621.USD","IE00B1BXHZ80.USD","BK4588","LU0203345920.USD","LU0861579265.USD","LU1093756168.USD","LU1116320737.USD","LU1116320901.HKD","SG9999014575.USD","IE000M9KFDE8.USD","SG9999013999.USD","IE00BN8TJ469.HKD","SG9999002232.USD","LU0265550359.USD","LU0208291251.USD","IE00BLSP4452.SGD","LU2324357040.USD","SWTX","LU1989772840.SGD","IE00BBT3K403.USD","MRK","LU1162221912.USD","LU1037948897.HKD","LU1699723380.USD","LU2361044865.SGD","LU1066053197.SGD","LENZ","LU1057294990.SGD","LU1037948541.HKD","LU1061106388.HKD","LU2361044949.HKD","IE00BLSP4239.USD","LU0289739699.SGD","LU1066051498.USD","SG9999001176.USD","LU1066051811.HKD","LU1934455194.USD","LU0965509101.SGD"],"gpt_icon":1},{"id":"2510289247","title":"独家-德国默克公司就收购美国生物技术公司 Springworks 进行深入谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2510289247","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510289247?lang=zh_cn&edition=full","pubTime":"2025-02-11 04:38","pubTimestamp":1739219934,"startTime":"0","endTime":"0","summary":"独家-德国默克公司就收购美国生物技术公司 Springworks 进行深入谈判默克证实收购 Springworks 的谈判已进入后期阶段证实了路透早些时候的报导,即交易可能在数周内达成Springworks 的股价达到 2022 年 4 月以来的最高水平美国公司市值约 40 亿美元 第 2 段添加了默克公司的声明,第 4 和第 5 段更新了股价反应Sabrina Valle/Patricia Weiss. Springworks 拒绝对此置评。对Springworks公司的交易将成为默克公司近年来最大的医药交易之一,并将推动其不断扩大癌症治疗产品线的努力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL4T3P11M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B42XCP33.USD","LU2106854487.HKD","LU0234570918.USD","BK4585","IE00BGHQF631.EUR","LU1934455277.USD","LU0320765646.SGD","SG9999014542.SGD","IE00BSNM7G36.USD","BK4533","BK4592","LU0106261372.USD","LU1093756325.SGD","LU1221951129.SGD","LU1989772923.USD","IE00B2B36J28.USD","LU0965508806.USD","LU1069347547.HKD","IE00B1BXHZ80.USD","SGXZ57979304.SGD","LU0203345920.USD","LU0861579265.USD","SG9999014567.USD","BK4139","SG9999014575.USD","IE000M9KFDE8.USD","SG9999013999.USD","LU0882574055.USD","SG9999002232.USD","LU2347655156.SGD","LU0208291251.USD","SWTX","LU1244550577.SGD","BK4534","LU1674673428.USD","IE00BBT3K403.USD","LU0122379950.USD","LU0985320562.USD","LU1674673691.USD","LU1894683348.USD","LU1074936037.SGD","LU1914381329.SGD","IE00BVYPNW00.USD","LU2592432038.USD","IE0009355771.USD","LU0098860793.USD","LU1934455194.USD","LU1066051811.HKD","JNJ"],"gpt_icon":1},{"id":"2510786378","title":"独家-消息人士称,德国默克公司正在洽谈收购美国癌症生物技术公司 Springworks","url":"https://stock-news.laohu8.com/highlight/detail?id=2510786378","media":"路透中文","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510786378?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:47","pubTimestamp":1739198829,"startTime":"0","endTime":"0","summary":"独家-消息人士称,德国默克公司正在洽谈收购美国癌症生物技术公司 SpringworksSabrina Valle/Patricia Weiss. 路透纽约/法兰克福2月10日 - 据熟悉内情的人士透露,德国医疗保健和科技集团默克公司正在就收购美国癌症和罕见病制药商Springworks TherapeuticsSWTX.O 进行深入谈判。市值 30 亿美元的 Springworks 拒绝发表评论。对Springworks公司的交易将成为默克公司近年来最大的医药交易之一,并将推动其不断扩大癌症治疗产品线的努力。2015 年,默克同意以 170 亿美元的价格收购美国实验室设备供应商 Sigma-Aldrich。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL4T3P11BD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU1989772923.USD","LU0058720904.USD","LU2361044865.SGD","LU2133065610.SGD","LU1718418525.SGD","LU0211331839.USD","LU1032466523.USD","IE00BJT1NW94.SGD","IE00BDGV0183.EUR","SG9999014559.SGD","LU0122379950.USD","LU2347655156.SGD","LU1935042991.SGD","LU2361045086.USD","BK4559","SG9999014575.USD","BK4592","LU0265550946.USD","LU1267930813.SGD","LU0889566641.SGD","LU0345769128.USD","LU1291159041.SGD","JNJ","LU1093756168.USD","LU1914381329.SGD","LU1778281490.HKD","LU0203347892.USD","LU1929549753.HKD","LU0208291251.USD","IE00BLSP4452.SGD","LU2023250843.SGD","LU1894683264.USD","SG9999001176.SGD","LU1061106388.HKD","LU0466842654.USD","IE00B4R5TH58.HKD","LU1244550577.SGD","SGXZ57979304.SGD","BK4550","IE00BVYPNV92.GBP","BK4504","LU1732799900.SGD","LU1571399168.USD","LU1941712348.USD","SWTX","LU0965508806.USD","LU1074936037.SGD","LU1059921491.USD"],"gpt_icon":1},{"id":"2508216457","title":"Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508216457","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508216457?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:38","pubTimestamp":1738679901,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时38分,Springworks Therapeutics, Inc.股票出现波动,股价快速拉升5.14%。Springworks Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.10%。Springworks Therapeutics, Inc.公司简介:SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司,该公司采用精准医疗的方法,获取、开发和商业化改变生命的药物,用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223821987a4b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223821987a4b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SWTX","BK4139"],"gpt_icon":0},{"id":"2505001388","title":"【券商聚焦】摩根大通:2025年1月美国分析师关注名单出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2505001388","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505001388?lang=zh_cn&edition=full","pubTime":"2025-01-24 12:13","pubTimestamp":1737692030,"startTime":"0","endTime":"0","summary":"金吾财讯 | 摩根大通发布2025年1月美国分析师关注名单,多家公司被圈定为“买入”评级。消费板块里,成长型公司Abercrome & Fitch 目标价204美元;通用汽车则被看作价值股,目标价64美元。医疗保健行业中,众多成长型股票备受关注。如Eli Lily & Company目标价1100美元;Vertex Pharmaceuticals目标价280美元。在科技领域,微软作为成长股,目标价465美元;Broadcom目标价250美元。此外,名单还包含了近期四周的新增和移除股票信息。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/OTE1MjMxNjI4NTkwNjg5MDI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTE1MjMxNjI4NTkwNjg5MDI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"284688","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310799852.SGD","LU2108987350.USD","BK4152","LU0256863902.USD","IE00B19Z3B42.SGD","SG9999001440.SGD","LU2237443895.HKD","LU0211328371.USD","LU2347655156.SGD","IE00BYXW3230.USD","LU0198837287.USD","LU2324357040.USD","IE00B775SV38.USD","IE00BVYPNV92.GBP","LU0211327993.USD","LU1162221912.USD","LU0348723411.USD","LU0942090050.USD","CHRW","LU1093756168.USD","BK4533","LU0912757837.SGD","LU0070302665.USD","BK4581","LU0211326839.USD","LU1093756325.SGD","BK4574","GM","LU1815333072.USD","LU2505996681.GBP","LU2602419157.SGD","LU2430703095.HKD","JPM","AVGO","LU2360106780.USD","LU1670711040.USD","IE00BKDWB100.SGD","IE00BBT3K403.USD","IE00BJLML261.HKD","LU0096362180.USD","LU0433182093.SGD","BK4515","IE00BK4W5M84.HKD","SWTX","LU1153585028.USD","VRTX","LU1032466523.USD","AGCO","LU1934455194.USD","LU0553294199.USD"],"gpt_icon":1},{"id":"2503558849","title":"Springworks Therapeutics, Inc.盘中异动 股价大跌8.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503558849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503558849?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:31","pubTimestamp":1736778673,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时31分,Springworks Therapeutics, Inc.股票出现异动,股价快速下挫8.95%。Springworks Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.01%。Springworks Therapeutics, Inc.公司简介:SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司,该公司采用精准医疗的方法,获取、开发和商业化改变生命的药物,用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223113aba9302c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223113aba9302c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SWTX","LENZ"],"gpt_icon":0},{"id":"2502770765","title":"Guggenheim:维持SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由80.00美元调整至78.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502770765","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502770765?lang=zh_cn&edition=full","pubTime":"2025-01-09 03:41","pubTimestamp":1736365275,"startTime":"0","endTime":"0","summary":"Guggenheim:维持SpringWorks Therapeutics(SWTX.US)评级,由买入调整至买入评级, 目标价由80.00美元调整至78.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/09034147280150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SWTX","LENZ"],"gpt_icon":0},{"id":"2501789956","title":"Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501789956","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501789956?lang=zh_cn&edition=full","pubTime":"2025-01-07 23:57","pubTimestamp":1736265457,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日23时57分,Springworks Therapeutics, Inc.股票出现异动,股价大幅拉升5.65%。Springworks Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.29%。Springworks Therapeutics, Inc.公司简介:SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司,该公司采用精准医疗的方法,获取、开发和商业化改变生命的药物,用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107235737985e236e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107235737985e236e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","SWTX"],"gpt_icon":0},{"id":"2489115000","title":"Springworks Therapeutics, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489115000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489115000?lang=zh_cn&edition=full","pubTime":"2024-12-04 23:36","pubTimestamp":1733326589,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日23时36分,Springworks Therapeutics, Inc.股票出现异动,股价大幅拉升5.01%。Springworks Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.10%。Springworks Therapeutics, Inc.公司简介:SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司,该公司采用精准医疗的方法,获取、开发和商业化改变生命的药物,用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204233629971ba412&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204233629971ba412&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SWTX"],"gpt_icon":0},{"id":"2486888480","title":"Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.03%报41.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486888480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486888480?lang=zh_cn&edition=full","pubTime":"2024-11-27 00:05","pubTimestamp":1732637106,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日00时05分,Springworks Therapeutics, Inc.股票出现波动,股价快速上涨5.03%。截至发稿,该股报41.37美元/股,成交量29.0049万股,换手率0.39%,振幅5.14%。Springworks Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.36%。Springworks Therapeutics, Inc.公司简介:SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司,该公司采用精准医疗的方法,获取、开发和商业化改变生命的药物,用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127000506a25771d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127000506a25771d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SWTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.springworkstx.com","stockEarnings":[{"period":"1week","weight":0.0212},{"period":"1month","weight":0.6258},{"period":"3month","weight":0.5037},{"period":"6month","weight":0.3857},{"period":"1year","weight":0.0748},{"period":"ytd","weight":0.5583}],"compareEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":0.0233},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.0994},{"period":"1year","weight":0.2242},{"period":"ytd","weight":0.0434}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"SpringWorks Therapeutics, Inc.于2017年8月在特拉华州成立。该公司是一家临床阶段的生物制药公司,它使用精密医学来为患有严重疾病和癌症的服务不足的患者人群获取,开发和商品化改变生命的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.053201},{"month":2,"riseRate":1,"avgChangeRate":0.116331},{"month":3,"riseRate":0,"avgChangeRate":-0.099358},{"month":4,"riseRate":0.2,"avgChangeRate":-0.057063},{"month":5,"riseRate":0.6,"avgChangeRate":-0.021348},{"month":6,"riseRate":0.6,"avgChangeRate":0.056003},{"month":7,"riseRate":0.8,"avgChangeRate":0.083729},{"month":8,"riseRate":0.4,"avgChangeRate":-0.018602},{"month":9,"riseRate":0.4,"avgChangeRate":-0.093177},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.012169},{"month":11,"riseRate":1,"avgChangeRate":0.184166},{"month":12,"riseRate":0.666667,"avgChangeRate":0.134333}],"exchange":"NASDAQ","name":"SpringWorks Therapeutics, Inc.","nameEN":"SpringWorks Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.1","shortVersion":"4.31.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SpringWorks Therapeutics, Inc.(SWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SpringWorks Therapeutics, Inc.(SWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SpringWorks Therapeutics, Inc.,SWTX,SpringWorks Therapeutics, Inc.股票,SpringWorks Therapeutics, Inc.股票老虎,SpringWorks Therapeutics, Inc.股票老虎国际,SpringWorks Therapeutics, Inc.行情,SpringWorks Therapeutics, Inc.股票行情,SpringWorks Therapeutics, Inc.股价,SpringWorks Therapeutics, Inc.股市,SpringWorks Therapeutics, Inc.股票价格,SpringWorks Therapeutics, Inc.股票交易,SpringWorks Therapeutics, Inc.股票购买,SpringWorks Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SpringWorks Therapeutics, Inc.(SWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SpringWorks Therapeutics, Inc.(SWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}